MIR517C: A Potential Drug Target and Biomarker (G574492)

Target Name: MIR517C

NCBI ID: G574492

MIR517C

MIR517C: A Potential Drug Target and Biomarker

MIR517C, a microRNA (miRNA), has been identified as a potential drug target and biomarker for various diseases, including cancer. This molecule has been shown to play a critical role in the regulation of cell proliferation and has been associated with various cellular processes, including cell cycle progression, apoptosis, and tissue development.

The discovery and characterization of MIR517C

MIR517C was first identified as a non-coding RNA (ncRNA) in the blood of cancer patients using next-generation sequencing (NGS) technology. The RNA was shown to have a strong expression in various tissues and cells, including cancer cells, fetal tissues , and normal tissues.

To further study the function of MIR517C, researchers used a variety of techniques, including RNA sequencing, RNA interference (RNAi), and mass spectrometry (MS), to determine its potential role in cell proliferation and apoptosis. These studies revealed that MIR517C was involved in the regulation of cell cycle progression, apoptosis, and various cellular processes that are crucial for cancer development.

MIR517C's role in cancer

One of the most significant findings related to MIR517C is its involvement in the regulation of cell cycle progression, which is a critical step in cancer development. MIR517C has been shown to play a role in the establishment of the G1 phase of the cell cycle, which is when the cell prepares for cell division.

Research has shown that MIR517C promotes the G1 phase by inhibiting the activity of the protein kinase PDGFR-尾, which is involved in cell proliferation. This means that when MIR517C is expressed in cancer cells, it can promote their uncontrolled growth and the formation of tumors.

Another study found that MIR517C was involved in the regulation of apoptosis, which is the process by which cells undergo programmed cell death. This is important for the regulation of cell growth and the avoidance of uncontrolled cell proliferation that can lead to cancer.

MIR517C's potential as a drug target

The potential drug target for MIR517C is based on its involvement in cell cycle progression and apoptosis. Drugs that target MIR517C and inhibit its activity have the potential to be used as anti-cancer drugs.

One approach to targeting MIR517C is to use small interfering RNA (siRNA) to knockdown its expression in cancer cells. This has been shown to be an effective way to reduce the number of cancer cells in animals and is a potential clinical approach for targeting MIR517C.

Another approach to targeting MIR517C is to use drugs that specifically target its activity. One class of drugs that have been shown to inhibit the activity of MIR517C is the DNA damage-inducible kinase inhibitors (DDI). These drugs work by inhibiting the activity of MIR517C and have been shown to be effective in various types of cancer.

MIR517C as a biomarker

MIR517C has also been shown to be a potential biomarker for cancer. The high expression of MIR517C has been shown to be associated with the poor prognosis of cancer patients. This is because MIR517C has been shown to promote the survival of cancer cells and contribute to their ability to migrate and invade surrounding tissues.

In addition, MIR517C has also been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels form in the body. This is important for the delivery of drugs to cancer cells, and is a potential target for cancer immunotherapy.

Conclusion

MIR517C is a microRNA that has been shown to play a critical role in the regulation of cell proliferation and apoptosis. Its high expression and involvement in

Protein Name: MicroRNA 517c

The "MIR517C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR517C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets